Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 84

1.

Estrogen receptor alpha inhibits senescence-like phenotype and facilitates transformation induced by oncogenic ras in human mammary epithelial cells.

Liu Z, Wang L, Yang J, Bandyopadhyay A, Kaklamani V, Wang S, Sun LZ.

Oncotarget. 2016 Jun 1. doi: 10.18632/oncotarget.9772. [Epub ahead of print]

2.

Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer.

Kaklamani VG.

Oncologist. 2016 Jun 2. pii: theoncologist.2015-0366. [Epub ahead of print]

PMID:
27256875
3.

Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?

Kaklamani VG, Gradishar WJ.

J Natl Compr Canc Netw. 2015 Nov;13(11):1448-52. No abstract available.

PMID:
26553770
4.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW.

N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.

5.

BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential association.

Waisbren J, Uthe R, Siziopikou K, Kaklamani V.

BMJ Case Rep. 2015 Jul 6;2015. pii: bcr2014208830. doi: 10.1136/bcr-2014-208830.

PMID:
26150619
6.

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).

Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL, Jones J, Hartman AR, Meservey C, Jovanovic B, Helenowski I, Khan SA, Bethke K, Hansen N, Uthe R, Giordano S, Rosen S, Hoskins K, Von Roenn J, Jain S, Parini V, Gradishar W.

Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26.

PMID:
26006067
7.

Synchronous primary carcinoma of breast and ovary versus ovarian metastases.

Yadav BS, Sharma SC, Robin TP, Sams S, Elias AD, Kaklamani V, Kelly Marcom P, Schaefer S, Morris GJ.

Semin Oncol. 2015 Apr;42(2):e13-24. doi: 10.1053/j.seminoncol.2014.12.020. Epub 2015 Jan 12. Review. No abstract available.

PMID:
25843740
8.

Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.

Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R; National comprehensive cancer network.

J Natl Compr Canc Netw. 2014 Sep;12(9):1326-38.

PMID:
25190698
9.

Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.

Gordon AC, Gradishar WJ, Kaklamani VG, Thuluvath AJ, Ryu RK, Sato KT, Gates VL, Salem R, Lewandowski RJ.

J Vasc Interv Radiol. 2014 Oct;25(10):1523-32, 1532.e1-2. doi: 10.1016/j.jvir.2014.07.007. Epub 2014 Aug 22.

10.

Antipsychotic treatment in breast cancer patients.

Rahman T, Clevenger CV, Kaklamani V, Lauriello J, Campbell A, Malwitz K, Kirkland RS.

Am J Psychiatry. 2014 Jun;171(6):616-21. doi: 10.1176/appi.ajp.2013.13050650. Review.

PMID:
24880509
11.

Predicting benefit from imatinib: are we close?

Gandhi MD, Kaklamani VG.

Leuk Lymphoma. 2014 Nov;55(11):2421-2. doi: 10.3109/10428194.2014.909041. Epub 2014 Apr 22. No abstract available.

PMID:
24684225
12.

Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.

Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG; Northwestern Cancer Genetics Group.

Cancer. 2014 May 15;120(10):1557-64. doi: 10.1002/cncr.28577. Epub 2014 Feb 12.

13.

Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer.

Reddy SM, Sadim M, Li J, Yi N, Agarwal S, Mantzoros CS, Kaklamani VG.

Br J Cancer. 2013 Aug 20;109(4):872-81. doi: 10.1038/bjc.2013.441. Epub 2013 Aug 6.

14.

Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women's Health Initiative.

Kaklamani VG, Hoffmann TJ, Thornton TA, Hayes G, Chlebowski R, Van Horn L, Mantzoros C.

Breast Cancer Res Treat. 2013 Jun;139(2):461-8. doi: 10.1007/s10549-013-2546-6. Epub 2013 Apr 30.

15.

Paradigm of polyendocrine therapy in endocrine responsive breast cancer: the role of fulvestrant.

Nelson V, Rademaker A, Kaklamani V.

Chin Clin Oncol. 2013 Mar;2(1):10. doi: 10.3978/j.issn.2304-3865.2012.09.04. No abstract available.

16.

Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.

Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA.

Clin Cancer Res. 2013 May 15;19(10):2745-54. doi: 10.1158/1078-0432.CCR-12-3177. Epub 2013 Feb 26.

17.

Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases.

Kumthekar P, Grimm SA, Avram MJ, Kaklamani V, Helenowski I, Rademaker A, Cianfrocca M, Gradishar W, Patel J, Mulcahy M, McCarthy K, Raizer JJ.

J Neurooncol. 2013 Apr;112(2):247-55. doi: 10.1007/s11060-013-1055-0. Epub 2013 Jan 25.

PMID:
23354655
18.

A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts.

Bao Y, Giovannucci EL, Kraft P, Stampfer MJ, Ogino S, Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, Rifai N, Pollak MN, Cochrane BB, Kaklamani V, Lin JH, Manson JE, Fuchs CS, Wolpin BM.

J Natl Cancer Inst. 2013 Jan 16;105(2):95-103. doi: 10.1093/jnci/djs474. Epub 2012 Dec 14.

19.

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.

Gradishar WJ, Kaklamani V, Sahoo TP, Lokanatha D, Raina V, Bondarde S, Jain M, Ro SK, Lokker NA, Schwartzberg L.

Eur J Cancer. 2013 Jan;49(2):312-22. doi: 10.1016/j.ejca.2012.08.005. Epub 2012 Sep 3.

PMID:
22954665
20.

The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies.

Economopoulou P, Kaklamani VG, Siziopikou K.

Oncologist. 2012;17(11):1394-401. doi: 10.1634/theoncologist.2012-0163. Epub 2012 Aug 31. Review.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk